SCHEMBL3584784

SCHEMBL3584784

O=C(NCCCOP(=O)(O)O)c1cc(N(CCCl)CCCl)c([N+](=O)[O-])cc1[N+](=O)[O-]

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.39
NPC1 O15118 2/20 0.38
CYP3A4 P08684 2/20 0.38
POLB P06746 3/20 0.35
LMNA P02545 2/20 0.35
RAB9A P51151 1/20 0.35
PRMT5 O14744 1/20 0.34
WDR77 Q9BQA1 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
MAPT P10636 3/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
GAA P10253 1/20 0.33
HTT P42858 1/20 0.33
MAPK1 P28482 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CYP2C19 P33261 2/20 0.33
HPGD P15428 2/20 0.33
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2364823 0.90 NPC1 (0.38) ALDH1A1NPC1CYP3A4POLBLMNA
SCHEMBL3580044 0.87 ALDH1A1 (0.38) ALDH1A1NPC1CYP3A4POLBLMNA
SCHEMBL3582844 0.85 ALDH1A1 (0.39) ALDH1A1NPC1CYP3A4POLBLMNA
SCHEMBL8761948 0.82 ALDH1A1 (0.41) ALDH1A1NPC1CYP3A4POLBLMNA
SCHEMBL8640122 0.81 NPC1 (0.41) ALDH1A1NPC1CYP3A4POLBLMNA
SCHEMBL8761909 0.80 NPC1 (0.44) ALDH1A1NPC1CYP3A4POLBLMNA
SCHEMBL15572744 0.78 PRMT5 (0.36) ALDH1A1NPC1CYP3A4POLBLMNA
SCHEMBL15573266 0.78 THRA (0.37) ALDH1A1NPC1CYP3A4POLBLMNA
SCHEMBL3585095 0.77 NPC1 (0.36) ALDH1A1NPC1CYP3A4POLBLMNA
SCHEMBL3586420 0.76 KMT2A (0.40) NPC1CYP3A4POLBLMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629332-B2 Nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents AUCKLAND UNISERVICES LIMITED (NZ) 2009-12-08 US claimed
US-20070032455-A1 Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents AUCKLAND UNIVERVICES LIMITED (NZ) 2007-02-08 US claimed
US-20100010094-A1 Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents AUCKLAND UNISERVICES LIMITED (NZ) 2010-01-14 US disclosed
US-7629332-B2 Nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents AUCKLAND UNISERVICES LIMITED (NZ) 2009-12-08 US disclosed
US-20070032455-A1 Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents AUCKLAND UNIVERVICES LIMITED (NZ) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032455-A1 Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents NAPRT, NTPCR, PNP ALDH1A1 184/4885NPC1 1359/4885CYP3A4 477/4885
US-20100010094-A1 Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents NAPRT, NTPCR, QDPR ALDH1A1 164/4885NPC1 1461/4885CYP3A4 588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.